Price
No data yet.
Social Signal Score
Revenue
$247.53M+20841.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gunilla Christina Osswald
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 131
- Beta
- -0.67
- Country
- SE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 26.25
Financials
Revenue
$247.53M+20841.2%Net Income
$-11.17MEBITDA
$-10.96MFree Cash Flow
$0.00EPS (diluted)
$-0.12Shares Outstanding (diluted)
88.72M+40.7%Operating Expenses
$226.88MCash & Debt
$1.97BReturn of Capital
$0.00Dividend per Share
$0.21Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.99B | $1.02B | $11.52 |
| 2024 | $257.35M | $-177.08M | $-2.00 |
| 2023 | $616.00M | $229.25M | $2.59 |
| 2022 | $228.29M | $-11.18M | $-0.13 |
| 2021 | $23.15M | $-119.79M | $-1.36 |
| 2020 | $62.35M | $-68.52M | $-0.78 |
| 2019 | $281.77M | $88.47M | $1.00 |
| 2018 | $713.97M | $381.60M | $4.33 |
| 2017 | $140.71M | $15.16M | $0.22 |
| 2016 | $105.61M | $57.58M | $0.65 |
| 2015 | $41.57M | $3.71M | $0.06 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BRCTF's reported EPS growth of 69.5% a year over 10 years. Historical EPS growth of 70% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $42.78
- Implied price
- $1,198
- Return from $36.92
- 100.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $595.49 — today's price is already 93.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| 20.0% | 73.1% | 79.5% | 85.1% | 90.1% | 94.7% |
| 25.0% | 80.3% | 87.0% | 92.8% | 98.0% | 102.8% |
| 30.0% | 87.5% | 94.5% | 100.5% | 106.0% | 110.9% |
| 35.0% | 94.7% | 101.9% | 108.3% | 113.9% | 119.0% |
| 40.0% | 101.9% | 109.4% | 116.0% | 121.8% | 127.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (4)
- Newsprnewswire.com·35d ago·Neutral
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 20,200 stock options of series 2019/2028.
View source ↗ - Newsseekingalpha.com·41d ago·Positive
BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·48d ago·Neutral
BioArctic and Mesenkia enter oncology research collaboration STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge. The collaboration comb
View source ↗ - Newsprnewswire.com·48d ago·Neutral
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026, at 8:00 a.m. CEST. In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on August 26 at 9:30 a.m.
View source ↗
Earnings
Wed, Nov 25(in 7 weeks)
Consensus estimate $0.02 per share
Typical surprise +43.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 26$-0.01 vs $-0.03beat
- Wed, May 20$0.25 vs $-0.03beat
- Wed, Feb 18$-0.01 vs $-0.06beat
- Thu, Nov 13$-0.10 vs $-0.12beat
- Mon, Jun 30$0.11 vs $0.16miss
- Mon, Mar 31$1.15 vs $1.03beat
Estimates and results for BRCTF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in BRCTF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.